AEON Biopharma director awarded 222,684 RSUs

PALMISANO ROBERT J reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

PALMISANO ROBERT J reported acquisition or exercise transactions in this Form 4 filing.

AEON Biopharma director Robert J. Palmisano received an award of 222,684 restricted stock units (RSUs) of Class A Common Stock on June 17, 2026. The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the 2027 annual stockholders’ meeting, subject to continued service. Following this grant, his direct holdings total 258,705 shares.

Insider Trade Summary

Grant/Award: 222,684 shares

Grant/Award 1 txn

Insider PALMISANO ROBERT J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	222,684	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 258,705 shares (Direct)

Footnotes (1)

1. F1. Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

Key Figures

RSU grant size: 222,684 RSUs Post-grant holdings: 258,705 shares Grant price per share: $0.0000 per share

3 metrics

RSU grant size 222,684 RSUs Award of Class A Common Stock RSUs on June 17, 2026

Post-grant holdings 258,705 shares Total direct Class A Common Stock after transaction

Grant price per share $0.0000 per share Reported transaction price for RSU grant

Key Terms

restricted stock units, RSUs, vest in full, annual meeting of the Company's stockholders

4 terms

restricted stock units financial

"Represents an award of restricted stock units ("RSUs") granted on June 17, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vest in full financial

"The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary"

annual meeting of the Company's stockholders financial

"the date of the 2027 annual meeting of the Company's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AEON Biopharma (AEON) director Robert J. Palmisano receive in this Form 4?

He received an award of 222,684 restricted stock units of Class A Common Stock. These RSUs represent a stock-based compensation grant reported as an acquisition, not an open‑market purchase or sale.

How and when do Robert J. Palmisano’s new AEON RSUs vest?

The 222,684 RSUs vest in full on the earlier of the one‑year anniversary of June 17, 2026, or the 2027 annual stockholders’ meeting. Vesting requires that he continue serving through the applicable vesting date.

Is this AEON Biopharma Form 4 a stock purchase or a compensation grant?

It is a compensation-related grant of restricted stock units reported under transaction code A. The RSUs were awarded at no cash price per share, rather than acquired through an open‑market purchase.

How many AEON Biopharma shares does Robert J. Palmisano hold after this RSU grant?

After the 222,684 RSU award, his total reported direct holdings are 258,705 shares of Class A Common Stock. This figure reflects his position immediately following the reported transaction.

Does this AEON Form 4 involve any derivative securities or option exercises?

No, the filing reports only a grant of restricted stock units as non‑derivative Class A Common Stock. There are no option exercises, conversions, or other derivative transactions shown in the derivative summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 06:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PALMISANO ROBERT J

(Last) (First) (Middle)

C/O AEON BIOPHARMA, INC.

5 PARK PLAZA, SUITE 1750

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	06/17/2026		A		222,684	A	$0(1)	258,705	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

	/s/ Alexander Wilson, as Attorney-in-Fact, for Robert J. Palmisano	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)